ecteinascidin 743 has been researched along with Bone Marrow Diseases in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bertulli, R; Casali, PG; D'Incalci, M; Dileo, P; Gescher, A; Grosso, F; Jimeno, J; Piovesan, C; Sanfilippo, R; Stacchiotti, S | 1 |
D'Incalci, M | 1 |
Albella, B; Bueren, JA; Faircloth, G; Guzmán, C; Jimeno, J; López-Lázaro, L | 1 |
3 other study(ies) available for ecteinascidin 743 and Bone Marrow Diseases
Article | Year |
---|---|
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Dioxoles; Disease-Free Survival; Female; Humans; Liver Diseases; Male; Middle Aged; Premedication; Sarcoma; Steroids; Tetrahydroisoquinolines; Trabectedin | 2006 |
Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results" by Albella and colleagues.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow Diseases; Depsipeptides; Dioxoles; Hematopoietic Stem Cells; Humans; Isoquinolines; Megakaryocytes; Peptides, Cyclic; Tetrahydroisoquinolines; Trabectedin | 2002 |
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
Topics: Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Depsipeptides; Dioxoles; Doxorubicin; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Isoquinolines; Neoplasms; Peptides, Cyclic; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 2002 |